NO-delivering fluorescent beta-cyclodextrin polymer
A novel water-soluble β-cyclodextrin branched polymer covalently integrating a fluorescein moiety and a nitric oxide (NO) photodonor within its macromolecular
Category: CD as API
Carbohydrate drugs (Part 5) (Oligosaccharides, cyclodextrins)
First let’s talk about one of the biggest achievements in the history of cyclodextrin research: Sugammadex. Sugammadex (SGM) (BridionTM) (1a)
Lactosyl-β-cyclodextrin against Hepatomegaly in Niemann-Pick Type C Disease
The first paper in the special issue of Nanomaterials “Nanoconstructs Based on Cyclodextrins” has been published. Mono-lactosyl β-CD (mono-Lac-β-CD) diminished
Cyclodextrins as possible antidotes to box jellyfish venom
Box jellyfish (Chironex fleckeri) found in coastal waters from northern Australia and New Guinea north to the Philippines and Vietnam
Host-guest chemistry for the treatment of leishmania
Human leishmaniasis is an infectious parasitic disease endemic to about 90 countries by over 20 different Leishmaniasis species. It is
Cyclodextrins at HPLC 2019 Milan
HPLC 2019, the most important international conference in the field of high-performance liquid phase separations and related techniques, will be
CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer’s Disease
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
Novel polyrotaxane for Niemann Pick disease type C treatment
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
Antidepressant drug to treat sepsis
Sepsis is an often deadly complication of infection in which systemic inflammation damages the vasculature, leading to tissue hypoperfusion and
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical